Methotrexate -- the inexpensive anchor drug for the treatment of rheumatoid arthritis -- isn't being used optimally today, with few patients switching from the oral to the subcutaneous formulation or adding a second conventional disease-modifying anti-rheumatic drug (DMARD) before turning to a biologic, researchers found.
